97在线观看免费视频,久草精品在线,九九热久久免费视频

Panc 04.03

規格:

價格:

編號:B223978

品牌:Mingzhoubio

標準菌株

定量菌液

DNA

RNA

規格:

凍干粉

斜面

甘油

平板

加入購物車

在線咨詢收藏

產品名稱

Panc 04.03

商品貨號

B223978

Organism

Homo sapiens, human

Tissue

pancreas

培養基

Product Format

frozen

Morphology

epithelial

Culture Properties

adherent

Biosafety Level

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease

adenocarcinoma

Age

70 years adult

Gender

male

Ethnicity

White

Storage Conditions

liquid nitrogen vapor phase

Derivation

Panc 04.03 is a pancreatic adenocarcinoma epithelial cell line derived, in 1995, from a primary tumor removed from the head-of-the-pancreas of a male with pancreatic adenocarcinoma.

Clinical Data

70 years

Caucasian

male

Antigen Expression

MHC class I +; MHC class II -

Ref

Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602

Blood type O; Rh+

Oncogene

K-ras + Ref

Genes Expressed

cytokeratins 7 and 18 Ref

Cellular Products

cytokeratins 7 and 18

Ref

Tumorigenic

Yes

Effects

Yes, forms tumors in nude or SCID mice

Comments

The cell line exhibits a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine. RefJaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602

The cells have a reported plating efficiency of 80%. RefJaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602

Complete Growth Medium

The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium:

20 Units/ml human recombinant insulin
fetal bovine serum to a final concentration of 15%

Subculturing

Volumes used in this protocol are for 75 cm² flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.

Remove and discard culture medium.
Briefly rinse the cell layer with 0.25% (w/v) Trypsin-053mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
Add appropriate aliquots of the cell suspension to new culture vessels.
Incubate cultures at 37°C.

Subcultivation Ratio: 1:2 to 1:3
Medium Renewal: Add media once per week. Fluid change one to two times per week.

Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 10 in Culture of Animal Cells, a Manual of Basic Technique by R. Ian Freshney, 3rd edition, published by Alan R. Liss, N.Y., 1994.

Cryopreservation

Complete growth medium supplemented with 5% (v/v) DMSO. Cell culture tested DMSO is available as ATCC Catalog No. 4-X.

Culture Conditions

Temperature: 37°C

Atmosphere: Air, 95%; Carbon dioxide (CO₂), 5%

STR Profile

Amelogenin: X

CSF1PO: 12

D13S317: 11,12

D16S539: 11,12

D5S818: 11

D7S820: 8,12